We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 30

Chinese Ministry of Health issues guidance to strengthen anti-bribery control at public hospitals
  • Sidley Austin LLP
  • China
  • September 6 2012

On August 1, 2012, the Ministry of Health of China (“MOH”) issued the draft Guidance on Strengthening Anti-Bribery Control at Public Hospitals


Updates on international pricing issues for pharmaceutical and biologic products
  • Sidley Austin LLP
  • China, European Union, France, Germany, United Kingdom, USA
  • May 18 2012

Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies


China’s comprehensive health care reform plan: implications for pharmaceutical and device firms
  • Sidley Austin LLP
  • China
  • April 9 2009

On April 6, the State Council of China made public the Guideline on Further Reforming the Health Care System (the Guideline), and on the following day the Action Plan for Health Care System Reform: 2009 - 2011 (the Action Plan


Drug pricing reform: an opportunity and challenge
  • Sidley Austin LLP
  • China
  • March 25 2011

The Chinese National Development and Drug Commission ("NDRC"), the authority in charge of drug pricing, recently slashed the maximum retail price of 162 cardiovascular and anti-infective drug products by an average of 21


China’s new drug GMP significantly raises drug manufacturing standards
  • Sidley Austin LLP
  • China
  • February 17 2011

On February 12, 2011, after rounds of revisions that took more than 5 years, the Ministry of Health of China ("MOH") published the final version of China's new drug GMP ("GMP 2010"


Chinese CDE launches joint review for chemical drug and API applications and other life sciences regulatory updates
  • Sidley Austin LLP
  • China
  • June 16 2011

The Center for Drug Evaluation (CDE) of the Chinese State Food and Drug Administration (SFDA) released a notice on June 7, 2011, establishing joint review for applications for chemical drugs and their active pharmaceutical ingredients (APIs) with a view to improving drug approval efficiency


China further revises rules for foreign investment in pharmaceutical industry
  • Sidley Austin LLP
  • China
  • January 3 2012

On December 24, 2011, China’s National Development & Reform Commission published the amended Industry Catalogue for Foreign Investments


China strengthening controls over human genetic resources
  • Sidley Austin LLP
  • China
  • June 21 2011

The Ministry of Science and Technology (“MOST”), the Ministry of Health (“MOH”) and the National Population and Family Planning Commission (“MPFPC”) of the Peoples Republic of China jointly issued a Notice Concerning the Protection and Administration of Human Genetic Resources (“HGR Notice”) on June 2, 2011


NDRC takes serial measures to reduce drug prices
  • Sidley Austin LLP
  • China
  • May 14 2012

It has long been a policy objective of the Chinese Government to reduce drug prices in China while ensuring drug quality


MOH publishes new draft of Drug GSP regulation
  • Sidley Austin LLP
  • China
  • May 11 2012

On April 25, the Ministry of Health of China published a new draft of the Drug GSP for public comment, and key changes are: